Oncology Drug Shortages in the U.S.
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug shortages in the U.S.
Of the 210 oncologists surveyed, 83% reported a shortage in a cancer drug that they wanted to use to treat their patients. Of those, 94% of oncologists said that their patients' treatment was affected.
Clinical Pearls
Because of the drug shortages, oncologists were forced to make expensive drug substitutions. Despite the prevalence of drug shortage issues since 2006, Gogineni says, oncologists have received little guidance regarding what substitutions to make and ethical guidance about appropriate substitutions
- In a survey, 83% of oncologists reported a shortage in a cancer drug that they wanted to use to treat their patients
- Since 2006, oncologists have received little guidance regarding what substitutions to make and ethical guidance about appropriate substitutions
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
